The plaintiffs in nine cases against Big Pharma companies for alleged Zantac injuries are using a strategy to keep their nearly identical claims in Connecticut state court unconsolidated for trial by naming less than 100 people in each case.
The 853 plaintiffs scored a victory in the U.S. Court of Appeals for the Second Circuit when the court held in a 2-1 decision that the plaintiffs’ motion to consolidate was for pretrial purposes only, and they did not intend to seek a joint trial.
